FDA scientists set date to discuss next steps for Pepaxto

22 July 2022
us_fda_big

An upcoming meeting of the US regulator’s Oncologic Drugs Advisory Committee (ODAC) will discuss the benefit/risk profile of Oncopeptides’ (STO: ONCO) Pepaxto (melphalan flufenamide).

The Swedish blood disorder specialist has previously  changed its mind about voluntarily withdrawing its New Drug Application (NDA) for Pepaxto, after studying overall survival (OS) data from the Phase III OCEAN study.

Pepaxto was approved under the US Food and Drug Administration’s accelerated approval scheme as a later-line option for people with multiple myeloma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical